BioCentury
ARTICLE | Clinical News

Pain gains on Remoxy, pipeline updates

May 13, 2015 2:36 AM UTC

Pain Therapeutics Inc. (NASDAQ:PTIE) jumped $0.68 (35%) to $2.62 on Tuesday after the company gave a corporate update and said it would resubmit an NDA in 1Q16 for Remoxy, its high viscosity capsule formation of oxycodone.

Pfizer Inc. (NYSE:PFE) returned rights to Remoxy following an internal review of studies conducted to address a June 2011 complete response letter from FDA. Pain said it believed it could resubmit the NDA based on existing data without conducting any new clinical studies, although it intends to conduct non-clinical work (see BioCentury Extra, Oct. 27, 2014). ...